AR SB136

Allows patients with life-threatening or severely debilitating illnesses to access individualized investigational treatments (drugs, biological products, or devices customized based on the patient's genetic profile, such as gene therapy or neoantigen vaccines) that have not been FDA-approved

Requires patients to have physician documentation confirming their diagnosis, consideration of all FDA-approved options, a recommendation based on genomic analysis, and written informed consent acknowledging risks including potential for worsened symptoms or hastened death

Manufacturers operating within eligible facilities (those with Federalwide Assurance for human subject protection) may offer treatments at no cost or charge actual manufacturing costs, but are not required to provide access

Prohibits state licensing boards from taking action against medical professionals' licenses and bars state agencies from blocking patient access; provides civil liability immunity for involved parties except in cases of gross negligence or willful misconduct

Insurance companies and Arkansas Medicaid are not required to cover these treatments, and patients' heirs are not liable for outstanding treatment-related debts if the patient dies